Sample description (447 patients)
| Per cent | Mean±SD | Range | n | |
|---|---|---|---|---|
| Age in 2009 (years) | 52.0±12.5 | 14–86 | 447 | |
| Disease duration in 2009 (years) | 16.1±8.1 | 5–49 | 440 | |
| Medication | 447 | |||
| NSAIDs | 29.3 | |||
| Cortisone ≤7.5 mg | 53.0 | |||
| Cortisone >7.5 mg | 16.1 | |||
| Antimalarials | 41.2 | |||
| Methotrexate | 9.8 | |||
| Azathioprine | 18.8 | |||
| Ciclosporine | 2.2 | |||
| Cyclophosphamide | 1.1 | |||
| Mycofenolatmofetil (MMF) | 13.0 | |||
| Medication groups | 447 | |||
| NSAIDs or no medication | 14.3 | |||
| Antimalarials and/or steroids, possible NSAIDs | 40.3 | |||
| Immunosuppressants, possible NSAIDs, antimalarials, steroids | 45.4 | |||
| Occupation type | 443 | |||
| Retired | 50.1 | |||
| Employees | 29.6 | |||
| Unemployed | 12.9 | |||
| Worker | 3.8 | |||
| Self-employed | 2.9 | |||
| Pupils/students | 0.7 | |||
| Physical functioning (0–100) (SF-36-pfi) | 62.4±27.5 | 0–100 | 447 | |
| SF-12 PCS | 37.9±11.0 | 11.0–62.9 | 414 | |
| SF-12 MCS | 46.1±11.7 | 18.4–69.5 | 414 | |
| SLAQ score | 14.8±7.0 | 0–37 | 446 | |
| VFS score | 26.7±19.2 | 0–70 | 424 | |
| SLICC/ACR DI | 2.8±2.9 | 0–21 | 407 | |
| PRSS catastrophising | 1.1±0.8 | 0–4.1 | 426 | |
| PRSS coping | 2.8±0.9 | 0–4.8 | 431 |
Data are percentages (%), means, SD and ranges.
N, number of cases; NSAIDs, non-steroidal anti-inflammatory drugs; PRSS, Pain-Related Self Statements Scale; SF-12 MCS, SF-12 Mental Component Summary; SF-12 PCS, SF-12 Physical Component Summary; SF-36-pfi, 36-item short-form physical functioning index; SLAQ, Systemic Lupus Activity Questionnaire; SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; VFS, Vanderbilt Fatigue Score.